Ignite Creation Date:
2024-05-06 @ 2:49 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04433546
Status:
TERMINATED
Last Update Posted:
2020-12-11
First Post:
2020-05-28
Brief Title:
Pemziviptadil PB1046 a Long-acting Sustained Release Human VIP Analogue Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome ARDS
Sponsor:
PhaseBio Pharmaceuticals Inc
Organization:
PhaseBio Pharmaceuticals Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Cardiac Infarct |
| Acute Respiratory Distress Syndrome |
| Coronavirus |
| Hypoxic Respiratory Failure |
| Hypoxemic Respiratory Failure |
| Respiratory Complication |
| Respiratory Insufficiency |
| Cardiac Dysfunction |
| Pneumonia |
| Pulmonary Edema |
| Pulmonary Inflammation |
| Respiratory Failure |
| Cytokine Storm |
| COVID 19 |
| SARS-CoV-2 |
| Cardiac Event |
| Cardiac Complication |
| Cardiac Failure |